IQAI Iq-ai Limited

TIDMIQAI

RNS Number : 1476K

IQ-AI Limited

03 May 2022

3 May 2022

IQ-AI Ltd

("IQ-AI" or the "Company")

IB Neuro's Quantitative Mapping Method Assesses Metastatic Tumors

Study Shows DSC MRI Perfusion Distinguishes Tumor from Non-Tumor Tissue

Milwaukee - 3 May 2022: Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI Limited, (OTCQB: IQAIF) (LSE: IQAI), notes a recent study published in the American Journal of Neuroradiology entitled: DSC Perfusion-Derived Fractional Tumor Burden and Relative CBV Differentiate Tumor Progression and Radiation Necrosis in Brain Metastases Treated with Stereotactic Radiosurgery.

The retrospective study, led by Dr. Michael Iv, MD, Clinical Associate Professor at Stanford University, used IB Software and other advanced imaging methods to evaluate metastatic brain tumors previously treated with a very precise form of radiation therapy called stereotactic radiosurgery. The goal was to determine which, if any, imaging technology could reliably distinguish between progressive tumor and radiation necrosis (non-tumor) tissue. The study concluded that IB Neuro's dynamic susceptibility contrast magnetic resonance imaging (DSC-MRI) perfusion-derived maps were able to make this distinction whereas the other methods to which it was compared could not. Those other methods included dynamic contrast enhanced (DCE) imaging, arterial spin labeling (ASL) which is an MRI technique that uses the body's own blood as a contrast agent to compute blood flow measurements, and positron emission tomography (PET) which can detect metabolic differences in tissue.

DSC-MRI is well established as the most robust and clinically adopted method for response assessment in high-grade (HG) primary brain tumors. Numerous studies have demonstrated the accuracy and reproducibility of IB Neuro's DSC platform and, specifically, its standardized measurement of relative cerebral blood volume (rCBV) to distinguish tumor from non-tumor tissue in HG tumors. This study is the first to replicate this method in metastatic brain tumors. The results are positive news for treatment teams who currently must rely on contrast-enhanced MRI to answer the basic question - is the enhancing region tumor, or is it an effect due to treatment?

Metastatic brain tumors are ten times more prevalent than primary brain tumors. This year in the US alone, it is expected that 220,000 people will be diagnosed with a metastatic brain cancer. Moreover, advances in treatment therapy are helping metastatic brain tumor patients live longer with improved quality of life. Thus, this number is expected to increase over time. Up to 50% of all cancers will eventually metastasize to the brain.

The study referred to IB's standardized rCBV (sRCBV) measurement. Standardization is an exclusive calibration technology that is built-in to IB Neuro. Fully automated, standardization translates the relative MRI image intensities to a fixed and consistent quantitative scale. This machine-learned technology is applied once for all scanner platforms, field strengths, and patients, and enables direct quantitative comparison between scans. It has been shown superior over other tissue normalization techniques; all of which require manual user input and are, therefore, less consistent and cannot be automated. The ability to obtain quantitative sRCBV values on a per-voxel basis differentiates IB Neuro from all other DSC-MRI platforms.

"This relevant and powerful study further validates our decision to develop IB Trax(TM). Incorporating our quantitative Delta T1 (patent-pending) and sRCBV maps will help neuroradiologists track and monitor brain metastases over time and potentially boost their accuracy and efficiency," said Trevor Brown, CEO and Chairman of IQ-AI, Ltd.

The Directors of the Company accept responsibility for the contents of this announcement

-ENDS-

For further information, please contact:

 
 IQ-AI Limited 
  Trevor Brown/Brett Skelly/Vinod Kaushal 
  Tel: 020 7469 0930 
 
   Peterhouse Capital Limited (Financial Adviser and Broker) 
   Lucy Williams/Heena Karani 
   Tel: 020 7220 9797 
 

About IQ-AI Limited

IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF), the parent company of Wisconsin-based Imaging Biometrics, LLC (IB), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation EU 596/2014 as it forms part of retained EU law (as defined in the European Union (Withdrawal) Act 2018).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDXXLFBLELFBBK

(END) Dow Jones Newswires

May 03, 2022 09:21 ET (13:21 GMT)

Iq-ai (LSE:IQAI)
Historical Stock Chart
From Mar 2024 to Apr 2024

Iq-ai (LSE:IQAI)
Historical Stock Chart
From Apr 2023 to Apr 2024